Human monoclonal IgG1 antibody, binds and blocks p40 of IL-12 and IL-23
Plaque psoriasis in adults, in ETA, IFX, ADA, UST and SEC also psoriatic arthritis, in ETA: indicated from 6 years of age
Under SVK Contract
Treatment of adult patients with severe psoriasis (Def. in USZ and Swiss S1 Guideline): PASI > 10 or BSA > 10 and/or DLQI > 10) in which UVB and PUVA or one of the following three systemic therapies (ciclosporin, methotrexate, acitretin) have not shown therapeutic success. In Iximab, additional failure of another TNF blocker approved for psoriasis
Blood count, liver enzymes, creatinine, U status, swan shaft test in urine, CRP/ ESR. Screening for HBV, HCV, HIV and tuberculosis incl. Rx thorax. Optional: ANA, HLA-Cw6 (personalized medicine as not yet validated response predictor for Ustekinumab)
PASI, (PrecisePASI for greater accuracy once PASI < 10), DLQI after 12 and 24 weeks.
3.8 - 5.1 %, association with clinical loss of efficacy
Absolute contraindications: Active infections including TB, pregnancy and breastfeeding. Relative contraindications: Malignant tumours, except treated basal cell carcinomas and lymphoproliferative diseases, live vaccinations. Simultaneous immunosuppressive therapy, to active infections: HBV
Local reactions at the injection site, upper respiratory tract infections, infections, cellulite, depression, vertigo, headache, pharyngolaryngeal pain, diarrhea, pruritus, back pain, myalgia, fatigue
Cancer risk is slightly increased for non-melanoma skin carcinomas, but not for other tumors
We and our partners are using technologies like cookies and process personal data like the IP-address or browser information in order to personalize the advertising that you see. This helps us to show you more relevant ads and improves your internet experience. We also use it in order to measure results or align our website content. Because we value your privacy, we are herewith asking for your permission to use these technologies. You can always change/withdraw your consent later.